Stocks making the biggest moves premarket: Zillow, Peloton, Sandisk, Moderna & more

Premarket movers were broadly mixed: Peloton sank ~14% after Q4 EPS of $0.13 matched estimates but active paying subscribers fell 8.8% YoY, while Sandisk slid ~10% on Q1 revenue guidance of $10.3B–$10.8B vs $10.47B consensus. Positives included Moderna shares up ~4% after FDA approval of mFlusiva for adults 50+, and IonQ rising ~3.9% as full-year revenue guidance ($280M–$290M) topped the $268.6M consensus. On the downside, Figma fell ~14% on soft adjusted operating income guidance ($125M–$135M vs $133.2M consensus), and Western Digital dropped >15% with Q1 revenue/EPS projections below expectations.

Analysis

The market is punishing forward visibility, not just quarter-to-quarter beats. That makes the high-multiple consumer/internet names the weakest links: APP, DUOL, FIG, and PTON all look vulnerable to further multiple compression if management teams cannot re-accelerate bookings, subscribers, or retention within 1-2 quarters. PTON is the cleanest structural loser because shrinking paid users implies the connected-fitness install base is aging faster than it can be replenished, which pressures both subscription ARPU leverage and the resale ecosystem that supports new-bike demand.

By contrast, DASH and IONQ are getting rewarded for scarcity of visible growth, but the quality of that growth matters. DASH has a better path to durable operating leverage because demand is broader and less narrative-driven; IONQ still depends on converting early revenue into repeatable enterprise spend, so the move can fade if bookings concentration or customer timing disappoints over the next 1-3 quarters. MRNA’s approval is only a tactical positive unless channel inventory, reimbursement, and uptake data show a real seasonal pull-through; otherwise it remains a platform story with limited immediate P&L translation.

The most important second-order signal is in memory/storage: WDC and SNDK weakness can spill into capex expectations for semiconductor equipment and into cloud/PC inventory discipline. If pricing softens again, this becomes a months-long estimate reset cycle rather than a one-day reaction. Contrarian view: the consensus may be overreacting to headline beats/misses and underweighting balance-sheet and FCF durability; that argues for owning cash-generative names on weakness and fading the most crowded short-duration growth stories.

Key Decisions for Investors

• Short APP on any post-open bounce; use a 2-4 week horizon. Risk/reward favors another 15-25% downside if the market decides the guide implies slower ad demand and weaker estimate revisions into the next print.
• Pair long DASH / short BMBL for 1-3 months. DASH has a clearer operating leverage path and less category fragility; BMBL remains exposed to weak retention and poor monetization, so the spread should widen if consumer spend stays selective.
• Avoid chasing IONQ after the pop; if long, use a call spread only after confirming the next quarter’s bookings conversion. The trade works only if enthusiasm turns into repeat enterprise revenue, otherwise the stock can give back the move quickly.
• Watch WDC and SNDK as a semiconductor-cycle alert rather than an immediate short. If both keep fading and memory pricing rolls over, consider a bearish pair versus semicap names over 1-3 months; if WDC holds its gap and pricing stabilizes, the selloff is likely overdone.
• Treat MRNA as a tactical trade only if follow-through data appears in flu uptake/reimbursement. A small starter long is acceptable on weakness, but the risk/reward is limited until channel demand proves the approval can move near-term revenue.